The burgeoning landscape of therapeutic interventions for obesity disorders has witnessed considerable attention focused on GLP-3 analogues and, more recently, the dual GIP and GLP-3 agonist retatrutide. While both classes demonstrate remarkable efficacy in achieving glycemic control and facilitating significant weight management, key distinctions … Read More

The burgeoning landscape of innovative treatments for body management has glp seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting considerable weight loss – they exhibit intriguing differences in thei… Read More